CVS Health Corporation (NYSE:CVS) – Analysts at Leerink Swann reduced their FY2018 EPS estimates for shares of CVS Health Corporation in a research note issued to investors on Tuesday. Leerink Swann analyst D. Larsen now anticipates that the pharmacy operator will earn $6.40 per share for the year, down from their prior forecast of $6.45. Leerink Swann has a “Buy” rating and a $90.00 price objective on the stock.

CVS Health Corporation (NYSE:CVS) last announced its quarterly earnings data on Tuesday, August 8th. The pharmacy operator reported $1.33 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.31 by $0.02. CVS Health Corporation had a return on equity of 17.47% and a net margin of 2.93%. The company had revenue of $45.69 billion for the quarter, compared to analyst estimates of $45.36 billion. During the same quarter in the previous year, the company earned $1.32 EPS. The firm’s revenue for the quarter was up 4.5% compared to the same quarter last year.

COPYRIGHT VIOLATION NOTICE: “Leerink Swann Weighs in on CVS Health Corporation’s FY2018 Earnings (CVS)” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/06/leerink-swann-weighs-in-on-cvs-health-corporations-fy2018-earnings-cvs.html.

Several other equities research analysts have also commented on CVS. Jefferies Group LLC restated a “hold” rating and issued a $82.00 price target on shares of CVS Health Corporation in a research note on Friday, June 9th. Vetr lowered shares of CVS Health Corporation from a “strong-buy” rating to a “buy” rating and set a $88.97 price objective on the stock. in a research note on Monday, June 12th. Cowen and Company reiterated an “outperform” rating and set a $86.00 price objective on shares of CVS Health Corporation in a research note on Tuesday, June 13th. Needham & Company LLC assumed coverage on shares of CVS Health Corporation in a research note on Tuesday, June 27th. They set a “hold” rating on the stock. Finally, Guggenheim reiterated a “buy” rating on shares of CVS Health Corporation in a research note on Monday, July 3rd. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and fifteen have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $89.56.

Shares of CVS Health Corporation (NYSE:CVS) traded down 1.95% during midday trading on Friday, reaching $79.32. The company’s stock had a trading volume of 2,230,522 shares. CVS Health Corporation has a 1-year low of $69.30 and a 1-year high of $88.92. The stock has a 50 day moving average of $79.69 and a 200-day moving average of $79.05. The company has a market capitalization of $80.63 billion, a P/E ratio of 15.80 and a beta of 0.92.

Institutional investors have recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. boosted its stake in CVS Health Corporation by 3.2% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 176,294 shares of the pharmacy operator’s stock worth $13,840,000 after purchasing an additional 5,478 shares during the period. Fiduciary Trust Co. boosted its stake in CVS Health Corporation by 1.2% in the 1st quarter. Fiduciary Trust Co. now owns 366,007 shares of the pharmacy operator’s stock worth $28,732,000 after purchasing an additional 4,265 shares during the period. British Columbia Investment Management Corp boosted its stake in CVS Health Corporation by 3.7% in the 1st quarter. British Columbia Investment Management Corp now owns 561,299 shares of the pharmacy operator’s stock worth $44,062,000 after purchasing an additional 19,794 shares during the period. Bahl & Gaynor Inc. boosted its stake in CVS Health Corporation by 1.1% in the 1st quarter. Bahl & Gaynor Inc. now owns 14,922 shares of the pharmacy operator’s stock worth $1,171,000 after purchasing an additional 167 shares during the period. Finally, Independent Advisor Alliance boosted its stake in CVS Health Corporation by 6.7% in the 1st quarter. Independent Advisor Alliance now owns 26,460 shares of the pharmacy operator’s stock worth $2,038,000 after purchasing an additional 1,652 shares during the period. 81.49% of the stock is owned by hedge funds and other institutional investors.

In related news, insider Larry J. Merlo sold 241,150 shares of the firm’s stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $83.07, for a total value of $20,032,330.50. Following the completion of the transaction, the insider now owns 299,255 shares of the company’s stock, valued at approximately $24,859,112.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Richard J. Swift sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $79.62, for a total transaction of $199,050.00. Following the completion of the transaction, the director now directly owns 3,258 shares of the company’s stock, valued at approximately $259,401.96. The disclosure for this sale can be found here. Insiders have sold 716,625 shares of company stock valued at $58,318,431 over the last 90 days. 0.61% of the stock is currently owned by insiders.

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 3rd. Investors of record on Tuesday, October 24th will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 2.47%. The ex-dividend date of this dividend is Monday, October 23rd. CVS Health Corporation’s payout ratio is 39.92%.

CVS Health Corporation Company Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Earnings History and Estimates for CVS Health Corporation (NYSE:CVS)

Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.